Equities

Biogen Inc

0R1B:LSE

Biogen Inc

  • Price (USD)199.18
  • Today's Change13.17 / 7.08%
  • Shares traded1.47k
  • 1 Year change38.89%
  • Beta0.1510
Data delayed at least 20 minutes, as of Feb 06 2026 19:11 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

  • Revenue in USD (TTM)10.07bn
  • Net income in USD1.61bn
  • Incorporated1997
  • Employees7.61k
  • Location
    Biogen Inc225 Binney StreetCAMBRIDGE 02142United StatesUSA
  • Phone+1 (302) 351-3367Fax+1 (302) 636-5454
  • Websitehttps://www.biogen.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		0R1B:LSE since
announced		Transaction
value
Alcyone Therapeutics IncAnnounced18 Sep 202518 Sep 2025Announced37.49%85.00m
Data delayed at least 20 minutes, as of Feb 06 2026 19:11 GMT.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.